distinct chromosomes. Almost all mammalian cells and tissues studied express multiple SRIF receptors but the combination Somatostatin (SRIF) is a potent antiproliferative signal for of receptor expression is cell and tissue type specific (3) . both normal and tumoral mammalian cells and an altera-SRIF receptors have been identified in a variety of human tion in the SRIF receptor expression pattern has been tumors. The most studied among them are those of neuroendoassociated with carcinogenesis. In the present study, the crine (e.g. GH-and TSH-producing pituitary adenomas), relevance of SRIF signaling to human male germ cell endocrine (e.g. enteropancreatic tumors, adrenal pheochromotumors was assessed at the receptor level. The expression cytomas and medullary thyroid carcinomas) and nervous (astroof five SRIF receptor (sst1-sst5) mRNAs was estimated by cytomas, neuroblastomas and meningiomas) origin. All these RT-PCR and compared between normal and tumoral testes. All 12 normal testicular tissues studied contained tumors express more than one of the five cloned SRIF receptors sst3 and sst5 receptor transcripts whereas sst4 was present (4) (5) (6) (7) . Their normal tissue counterparts also display multiple in almost all (11 of 12). sst1 transcripts were consistently SRIF receptors (2). The cancer etiology is in many instances absent while the majority (11/12) of normal samples studied associated with an alteration in SRIF receptor expression did not contain sst2 mRNA. Parallel assessment of SRIF pattern (2, 8, 9) . Moreover, the loss of a particular SRIF receptor receptor mRNAs in 10 seminoma testicular germ cell (i.e. sst2) has been associated with mechanisms underlying tumors showed expression of a single receptor type, sst5, carcinogenesis in the pancreas (8, 10) . Otherwise, knowledge in all samples analyzed. All seminoma samples were about SRIF receptor status of a given tumor is currently depleted in transcripts corresponding to sst1 and sst2 considered a valuable diagnostic and therapeutic criterion (11) . receptors while either sst3 or sst4 mRNAs were absent For example, the demonstration of sst2/sst5 receptor expression in almost all (9 of 10) tumoral samples studied. The in different carcinoid tumors provided the rationale for the use comparison of SRIF receptor expression between normal of synthetic SRIF agonists such as SMS201995 and BIM23014 tissue and seminoma tumors thus points to a selective loss in their clinical management (12) (13) (14) . of sst3 and sst4 mRNA expression in seminomas. Altogether Testicular cancers are rare malignancies (3-7/100 000) these data indicate that: (i) normal human testes are curable in up to 80% of cases in developed countries. The putative SRIF targets; (ii) loss of sst3 and sst4 SRIF remaining 20% are resistant to radio-and chemotherapy for receptor expression might be associated with seminoma reasons that remain unknown. The incidence of testicular carcinogenesis.
cancers has more than doubled over the world in the last 40 years, with a particularly strong tendency in northern and western Europe (15, 16 ). In addition, testicular tumors of germ Introduction cell origin, representing 95% of all testicular cancers, are the Carcinogenesis is commonly related to the abrogation of cell commonest solid tumor in 15-to 34-year-old men and are the division control by extracellular signals such as mitogens primary cause of death in this age group (16). Germ cell and antiproliferative molecules (1) . Besides growth factors and tumors are classified as non-seminomas or seminomas, each cytokines acting as either positive or negative regulators of accounting for~50% of germ cell tumors. Pathogenetic cell division, another family of signaling molecules, peptide mechanisms leading to the appearance of either of them are hormones, are involved in cell proliferation control. Signal unknown (15) . In particular, the absence of germ cell lines transduction of peptide hormone action is generally initiated render such mechanisms difficult to study. by activation of specific heptahelical transmembrane receptors.
SRIF has been found in both normal human testes (17) and As a corollary, these receptors are possible targets for carcinotesticular cancers of germ cell origin (18). However, previous genesis and are currently considered as potential tumor studies addressed only sst5 SRIF receptor expression in normal markers (2).
human testes (19), whereas a possible alteration in receptor Somatostatin (SRIF) is a peptide hormone with potent expression has not been assessed in these pathologies before. antiproliferative actions on different cell types under both
In the present work we therefore compared testicular SRIF physiological and pathological conditions. Additionally, SRIF receptor mRNA expression between samples obtained from is widely distributed throughout the central nervous system normal testes and seminomas using the RT-PCR approach.
Our data point to differential expression of sst1-sst5 receptors between the two experimental groups. a Numbers give the position of the first and the last primer nucleotide in the corresponding cDNA sequence. b These primers amplify both the sst2A and sst2B splice variants of the sst2 receptor.
Materials and methods

Subjects and tissue samples
Ten patients with testicular cancer of pure seminoma type, not metastatic to supradiaphragmatic nodal or visceral sites, were included in this study. The seminoma samples used were of stage I and II (disease limited to either testis, epididymis, spermatic cord or retroperitoneal lymph nodes, respectively). Biopsies of surrounding testicular tissues with histologically normal appearance were considered as normal controls. In addition, two subjects with histologically normal testes that had been orchiectomized after diagnosis of prostate cancer were also added to the experimental cohort. The patient age ranged from 26 to 56 years (mean 34.5). All testicular samples were collected by the Department of Pathology, Antiquaille Hospital, Lyon, France. Informed consent of the patients was obtained and approved by the Board of the Hospital. At surgery, tissue samples were divided into a few fragments: they were randomly either frozen and stored in liquid nitrogen for RT-PCR or fixed in 4% paraformaldehyde for histopathological analysis. Clinical diagnoses of seminomas (including serum negativity for α-fetoprotein) were confirmed cytologically based on the presence of immunoreactivity for placental alkaline phosphatase. Only specimens containing 100% normal or seminoma cancer cells were retained for study. Fig. 1 . Neither normal testes nor seminomas express sst1 receptor mRNA.
RNA extraction and RT-PCR conditions
Presented results correspond to the samples obtained from the first six TRIzol reagent (Life Technologies, Eragny, France) was used to extract total subjects (Table II , specimens N1-N6 and S1-S6). All remaining samples cellular RNA and DNA from tissue samples. In order to exclude any genomic (specimens N7-N12 for normal tissues and S7-S10 for seminomas, Table  DNA (Table I) .
In order to be able to compare the expression of sst1-sst5 receptor mRNAs ethidium bromide staining. They are shown in Figures 1-5 (for sst1-between different subjects we attempted to perform a co-amplification of sst5 receptors, respectively) for six representative normal (N1-N6) and six PCR fragments corresponding to each individual receptor, with β-actin used seminoma (S1-S6) samples; the remaining results are summarized in Table  as an internal standard. A compromise (compared with the parameters that III. However, all exceptions (e.g. a single sst2 mRNA-positive normal sample we have previously defined for these primers for human SRIF receptors; refs [corresponding to specimen N6, Table II ] out of 12 studied, Figure 2 ) are 20,21) MgCl 2 concentration of 2 mM and annealing temperature of 65°C systematically shown. All PCR products have been sequenced to confirm the were chosen for co-amplification. The co-amplification was successful for identity (data not shown). sst2, sst3 and sst5 receptors since, in addition to the amplification fragment Positive controls consisted of a reaction with genomic DNA. Negative of 661 bp corresponding to β-actin, products of the expected sizes (414, 221 controls consisted of a reaction performed as described above but without and 154 bp, respectively) for these receptors were observed (see Table I ). For addition of reverse transcriptase as a test of genomic DNA contamination. A the sst1 and sst4 receptors we were unable to perform a satisfactory cosecond negative control was carried out by replacing cDNA with water. amplification (i.e. with a single PCR product for each set of primers) with a total of four different sets of primers tested (data not shown). For these two receptors, the primer sequences shown in Table I were finally selected
Results
and amplifications were performed under the same conditions as for coamplification (i.e. 65°C, 2 mM MgCl 2 ) but without adding β-actin primers.
Clinicopathological data on tissue samples used in the present PCR amplification was carried out using a Trio-thermoblock (Biometra, study are given in Table II . The results shown in Figures 1-5 Kontron Instruments, Champagne au Mont d'Or, France) for 2.5 min of initial correspond to specimens N1-N6 for normal tissue and S1-S6 denaturation at 94°C, followed by 40 cycles of amplification (94°C for 60 s;
for seminomas that were obtained from cases 1-6 in Table II. 65°C for 60 s; 72°C for 60 s). Final elongation was achieved at 72°C for 5 min. Products of PCR amplification were visualized on 2% agarose gels by
Results corresponding to specimens N7-N12 and S7-S10 The samples are presented in the same order of appearance regarding their sst2 receptor mRNA. Presented results correspond to the samples obtained respective case origin as in Figures 1 and 2, i.e. they correspond to the first from the first six subjects (Table II , specimens N1-N6 and S1-S6). All six cases (Table II , specimens N1-N6 and S1-S6). All remaining samples remaining samples (specimens N7-N12 for normal tissues and S7-S10 for coming from the cases enumerated in Table II were positive (specimens seminomas, Table II ) were sst2 receptor mRNA negative (data not shown).
N7-N12 for normal tissues) or negative (specimens S7-S10 for seminomas) The only normal sample in which sst2 receptor mRNA could be detected for sst3 receptor mRNA expression (data not shown). The exception is the came from case number 6 (specimen N6, Table II ; lanes 23-24). The PCR seminoma sample shown by lanes 27-28 corresponding to case number 5 products are indicated by the arrows on the right and the size of amplified (specimen S5, Table II ) which was sst3 receptor mRNA positive. The PCR fragments is given in base pairs on the left (sst2 ϭ 414; β-actin ϭ 661).
products are indicated by the arrows on the right and the size of amplified Legends are identical to those given in Figure 1 .
fragments is given in base pairs on the left (sst3 ϭ 221; β-actin ϭ 661). Legends are identical to those given in Figure 1 . (Table II) are not presented in the figures; they are summarized in Table III. RT-PCR assays performed with the selected primers (Table I ) and under the chosen experimental conditions (2 mM MgCl 2 , 65°C, 40 cycles) allowed amplification of fragments of the expected sizes (Table I) in the respective positive controls in which genomic DNA was used as template (lanes 3 and 18 in Figures 1-5 ). Genomic DNA was used as a positive control for the size of amplified fragments since SRIF receptor genes contain no introns in their coding regions (3). As expected, in SRIF receptor-positive samples, the sizes of the amplified products obtained with cDNA used as template was identical to the sizes of the fragments amplified from genomic DNA (compare for example the size of fragments corresponding to the sst5 receptor amplified from any sample Figure 5 ). The regarding their respective case origin as in Figures 1-3, i.e. they correspond amplification products obtained from either genomic DNA to the first six cases (Table II , specimens N1-N6 and S1-S6). The results relevant to the only normal tissue sample in which sst4 mRNA could not be or cDNA with β-actin primers (internal standards) in codetected are given in lanes 6 and 7 corresponding to case number 2 amplification reactions (Figures 2, 3 and 5) were also identical (specimen N2, Table II ). The only sst4 mRNA-positive seminoma comes in size, as predicted, given that the chosen upstream and from case number 1 (specimen S1, Table II ) and is presented in lanes 10 downstream primers span a region within the same exon. performed in the absence of MMLV reverse transcriptase (Figures 1-5 , even numbered lanes from 4 to 14 and odd numbered lanes from 19 to 29) or when the template was of the expected size from genomic DNA used as a positive control (Figures 1 and 2, lanes 3 and 18) . Moreover, in replaced with water ( Figures 1-5, lanes 2 and 17) .
SRIF receptor mRNAs were detected in all normal and co-amplification reactions performed with sst2 and β-actin primers, a product corresponding to the latter was systematictumor testicle samples studied. Normal tissues express mRNAs for more than one receptor type (Figures 3-5) . In contrast, in ally found (Figure 2) . All normal testicle samples tested contained sst3 and sst5 mRNA. The sizes of fragments ampliseminomas, only expression of sst5 receptor mRNA was consistently observed ( Figure 5 ).
fied from cDNA were identical to those obtained with genomic DNA (positive control) used as template; fragments corresConcerning individual receptor transcripts, sst1 was absent in all normal samples (corresponding to specimens N1-N12 ponding to β-actin were co-amplified in all cases (Figures 3  and 5) . Similarly, 11 of 12 normal testicle samples (specimens obtained from cases 1-12 in Table II ; results corresponding to the first six specimens are shown in Figure 1 ) whereas sst2 N1 and N3-N12 in Table II , of which the first six, N1-N6, are shown in Figure 4 ) display sst4 transcripts; the sole sst4 mRNA was absent in 11 of 12 samples. The only normal testicle sample positive for sst2 receptor expression came from mRNA-negative sample (N2) corresponds to case number 2 (Table II and Figure 4 , lane 7). case number 6 (specimen N6, Table II and Figure 2, lane 24) . However, the selected sst1 and sst2 primers amplified fragments
No amplification product was obtained with primers specific Total   sst1  0  12  12  0  10  10  sst2  1  11  12  0  10  10  sst3  12  0  12  1  9  10  sst4  11  1  12  1  9  10  sst5  12  0  12  10  0  10 for sst1 and sst2 when seminoma cDNA was used as template (corresponding to specimens S1-S10 in Table II ; results Data corresponding to the first six cases described in Table II (specimens   1 and 2) . Nevertheless, the internal standard (a fragment N1-N6 and S1-S6) are given in lanes 4-9 and 19-24 (normal tissues) and lanes 10-15 and 25-30 (seminomas). All remaining samples presented in corresponding to β-actin) for co-amplification of sst2/β-actin Table II (specimens N7- corresponding to specimens S1-S6 in Table II) . Indeed, a 154 bp long product was obtained in PCR assays using either genomic or cDNA as template. 3, lanes 11, 13, 15, 26, 28 and 30) . The only seminoma The most striking difference between normal and tumoral samples expressing either sst3 (Figure 3 , lane 28) or sst4 samples was seen in relation to the expression of sst3 and (Figure 4 , lane 11) receptor mRNAs came from two different sst4 receptor transcripts. They were lost in 90% of tumors, subjects corresponding to specimens S5 and S1 obtained from contrasting with their presence in Ͼ90% of normal samples cases number 5 and number 1, respectively (Table II) . (shown in Figures 3 and 4 for the first six specimens presented
The expression of different SRIF receptors is summarized in Table II ). The absence of PCR products corresponding to in Table III . these two receptors is not due to inappropriate experimental conditions since fragments of the expected size were amplified Discussion from a genomic DNA (positive control) template for both sst3 and sst4 (Figures 3 and 4, lanes 3 and 18) . In addition, in co-
The results presented in this paper point to a selective loss of sst3 and sst4 receptor expression in testicular germ cell cancer amplification reactions of sst3/β-actin all seminoma samples displayed the PCR products corresponding to β-actin (Figure of seminoma type. However, sst3 and sst4 transcripts are each expressed in one of 10 seminoma samples tested. Since there sst3 and sst5 receptors (24). Similar conclusions on SRIFmediated regulation of testosterone secretion have also been was no amplification in RT-PCR reactions in which either template or MMLV reverse transcriptase was ommitted (negadocumented in animal models (25) . The presence of SRIF and its receptors in human (17; present study) and animal (26,27) tive controls), the observed fragments corresponding to sst3 and sst4 receptors obtained with these two seminomas could testes therefore supports the existence of auto/paracrine loops controling local testosterone secretion. In the light of this and not be the result of amplification of contaminating genomic DNA sequences. They are rather due to the well-documented in order to advance our understanding of SRIF testicular functions, a systematic evaluation of male gonadal parameters inter-individual variability in SRIF receptor expression by tumors (2). Alternatively, these two samples might have come as part of a routine survey of patients suffering from neuroendocrine tumors and undergoing long-term treatment with stable from two subjects in whom the cancerization process was less advanced than in the remaining nine subjects considered in SRIF analogs might produce precious information. Otherwise, concerning direct SRIF effects on germ cell our study. Indeed, the two cases (case number 5 for sst3 and case number 1 for sst4) are the only two patients in our proliferation, our data on the loss of SRIF receptor expression in seminomas (characterized by uncontrolled, high rate germ experimental cohort who displayed a tumor stage I seminoma with a maximal tumor diameter ഛ2 cm.
cell proliferation) are compatible with the proposed antiproliferative actions of this peptide. However, the possible In addition, our data show sst3, sst4 and sst5 SRIF receptor mRNA expression in normal human testes. Besides, expression negative regulation of germ cell proliferation by SRIF, such as has been documented in other cell types (3), remains to be of SRIF receptor mRNA is variable to some extent in normal testes as well. For example, the sst2 transcript was present in demonstrated explicitly in human and animal testicular models.
The establishment of germ cell lines as paradigms to study one normal sample whereas it was lacking in 11 other samples tested. The opposite was observed for sst4 receptor mRNA.
physio-pathological actions of SRIF in mammalian testes will probably help our understanding of underlying mechanisms. In contrast, expression of sst5 and absence of sst1 receptor mRNA expression appear much less polymorphous in both
In conclusion, our data indicate that a routine RT-PCR assessement of SRIF receptor expression in testicular biopsies normal and seminoma samples.
Given the heterogeneous SRIF receptor expression in differmay turn out to have important diagnostic and therapeutic implications. However, further studies at the international level ent tumor types (for a review see ref.
2), it is not possible to extrapolate the loss of sst3 and sst4 receptor mRNA expression are now required in order to confirm on a larger scale the data reported here on a relatively modest tumor cohort issuing from observed here in testicular cancer to the general pathogenetic mechanisms of carcinogenesis. Nevertheless, at this point it is a low (but increasing) frequency of seminoma. If confirmed by other studies, our data would suggest that a comparison of tempting to speculate on an emerging common tendency concerning these receptors. Thus, as in seminomas, in all SRIF receptor expression patterns in tumoral and surrounding normal testicular tissues revealing a loss of particular receptor tumors in which the expression pattern of SRIF receptors has been estimated, the sst3 receptor was rarely expressed or types might help to establish seminoma diagnosis. Knowledge of receptor expression patterns could also be used to develop absent. Indeed, small cell lung carcinoma (22), pancreatic, colorectal (8) and prostate (9) cancers as well as pituitary clinical trials for testing synthetic SRIF analogs in germ cell tumor therapies. Our results show that seminomas express the adenoma (4) lack this receptor type. In addition, in accordance with our data, the sst4 transcript was not found in pituitary sst5 receptor, which can be targeted with high affinity by stable SRIF agonists (e.g. SMS201995). This analog is already adenoma (4) and medullary thyroid carcinoma (7). However, it seems clear that, if relevant, such an absence or loss of sst3 used in the clinical treatment of a number of tumors (for a review see ref.
2). It is now worthwhile to compare the potential and sst4 receptor expression cannot be considered as the sole mechanism involved in carcinogenesis. For example, in therapeutic benefit of SRIF analogs with those provided by classical radio-and chemotherapies of seminomas. pancreatic carcinomas which lack the sst3 SRIF receptor, carcinogenesis was formally associated with loss of sst2 receptor expression. In an elegant study, Delesque and col
